Targeting the PI3K/Akt/mTOR pathway with the pan-Akt inhibitor GDC-0068 in PIK3CA-mutant breast cancer brain metastases

BACKGROUND: Activating mutations in the pathway of phosphatidylinositol-3 kinase (PI3K)/Akt/mammalian target of rapamycin (mTOR) occur in 43–70% of breast cancer brain metastasis patients. To date, the treatment of these patients presents an ongoing challenge, mainly because of the lack of targeted...

Description complète

Enregistré dans:
Détails bibliographiques
Publié dans:Neuro Oncol
Auteurs principaux: Ippen, Franziska Maria, Grosch, Julia Katharina, Subramanian, Megha, Kuter, Benjamin Macfarlane, Liederer, Bianca M, Plise, Emile G, Mora, Joana Liliana, Nayyar, Naema, Schmidt, Stephen Paul, Giobbie-Hurder, Anita, Martinez-Lage, Maria, Carter, Scott L, Cahill, Daniel P, Wakimoto, Hiroaki, Brastianos, Priscilla Kaliopi
Format: Artigo
Langue:Inglês
Publié: Oxford University Press 2019
Sujets:
Basic and Translational Investigations
Accès en ligne:https://ncbi.nlm.nih.gov/pmc/articles/PMC6827829/
https://ncbi.nlm.nih.gov/pubmed/31173106
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/neuonc/noz105
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires